What is HC Wainwright’s Estimate for LENZ Q1 Earnings?

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Analysts at HC Wainwright issued their Q1 2025 EPS estimates for LENZ Therapeutics in a research note issued to investors on Thursday, March 20th. HC Wainwright analyst M. Caufield expects that the company will post earnings of ($0.52) per share for the quarter. The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($2.18) per share. HC Wainwright also issued estimates for LENZ Therapeutics’ Q3 2025 earnings at ($0.73) EPS.

A number of other analysts have also recently weighed in on the stock. TD Cowen started coverage on shares of LENZ Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $60.00 price objective for the company. Citigroup boosted their price objective on shares of LENZ Therapeutics from $44.00 to $47.00 and gave the stock a “buy” rating in a research note on Thursday. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, LENZ Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $41.67.

LENZ Therapeutics Trading Up 0.7 %

Shares of LENZ Therapeutics stock opened at $26.49 on Friday. The firm has a fifty day simple moving average of $24.15 and a 200-day simple moving average of $27.03. LENZ Therapeutics has a 1-year low of $14.42 and a 1-year high of $38.93. The stock has a market capitalization of $728.50 million, a price-to-earnings ratio of -5.55 and a beta of 0.58.

LENZ Therapeutics (NASDAQ:LENZ) last issued its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.04).

Hedge Funds Weigh In On LENZ Therapeutics

Large investors have recently bought and sold shares of the stock. Harbor Capital Advisors Inc. acquired a new position in LENZ Therapeutics during the 4th quarter valued at $1,270,000. Parkman Healthcare Partners LLC acquired a new position in shares of LENZ Therapeutics in the 3rd quarter valued at $3,308,000. Barclays PLC raised its stake in shares of LENZ Therapeutics by 273.1% in the 3rd quarter. Barclays PLC now owns 16,463 shares of the company’s stock valued at $391,000 after buying an additional 12,051 shares in the last quarter. The Manufacturers Life Insurance Company bought a new position in shares of LENZ Therapeutics during the 3rd quarter worth about $743,000. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of LENZ Therapeutics by 197.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 123,371 shares of the company’s stock worth $2,929,000 after acquiring an additional 81,901 shares during the period. 54.32% of the stock is currently owned by institutional investors and hedge funds.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.